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Abstract
Background: Hepatitis C virus (HCV) belongs to Flaviviridae family of viruses. HCV represents a major challenge to
public health since its estimated global prevalence is 2.8% of the world’s human population. The design and
development of HCV vaccine has been hampered by rapid evolution of viral quasispecies resulting in antibody
escape variants. HCV envelope glycoprotein E1 and E2 that mediate fusion and entry of the virus into host cells are
primary targets of the host immune responses.
Results: Structural characterization of E2 core protein and a broadly neutralizing antibody AR3C together with E1E2
sequence information enabled the analysis of B-cell epitope variability. The E2 binding site by AR3C and its
surrounding area were identified from the crystal structure of E2c-AR3C complex. We clustered HCV strains using
the concept of “discontinuous motif/peptide” and classified B-cell epitopes based on their similarity.
Conclusions: The assessment of antibody neutralizing coverage provides insights into potential cross-reactivity of
the AR3C neutralizing antibody across a large number of HCV variants.
Background
Hepatitis C virus (HCV) is a major cause of viral hepatitis,
liver cirrhosis, and liver cancer. It was discovered in 1989
as a novel causative agent of hepatitis [1]. HCV is a grow-
ing health concern since it affects about 2.8% of the world
population and its prevalence is rising [2,3]. Each year,
there are more than 500,000 new HCV infections in Egypt,
the country with the highest HCV prevalence [4]. In the
United States, more people die from HCV than from
human immunodeficiency virus 1 (HIV-1) related disease
[5]. Six genotypes and multiple subtypes of HCV have
been identified to date. Approximately 75% of Americans
with HCV have genotype 1 of the virus (subtypes 1a or 1b),
and 20-25% have genotypes 2 or 3, with small numbers of
patients being infected with genotypes 4, 5, or 6 [6]. Effec-
tive vaccination would provide protection against this
global disease. However, the development of HCV vaccine
and identification of broadly neutralizing antibodies has
been hampered because HCV sequences mutate rapidly
generating escape variants [7], the non-neutralizing anti-
bodies to HCV envelope proteins interfere with neutraliz-
ing antibodies [8], and there is lack of 3D structural
information needed for vaccine development [9]. The first
crystal structure of broadly neutralizing antibody against
HCV has been published in 2013 [10].
The HCV envelope glycoproteins E1 and E2 form a het-
erodimer E1E2 that facilitates virus attachment and entry
into host cells and are targets for neutralizing antibodies
[11]. Recent progress in isolating and characterizing
HCV-neutralizing antibodies are instrumental for vaccine
discovery and design [12]. These HCV-neutralizing antibo-
dies were isolated from immunized mice [13-15], or from
patients chronically infected with HCV [16-20]. Giang
et al. [4], using an exhaustive panning strategy, identified
five distinct antigenic regions on the HCV E1E2, that were
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recognized by 73 human monoclonal antibodies (mAbs)
from an HCV immune phage-display antibody library.
Many of these antibodies showed broadly neutralizing
ability.
Structural characterization of HCV envelope glycopro-
teins is challenging because of the difficulty in obtaining
homogenous protein preparations [10,21-23]. Recently,
the crystal structure of E2 core bound to neutralizing
antibody AR3C has been crystalized [10], The antibody
AR3C belongs to a group of broadly neutralizing antibo-
dies that recognize antigenic region 3 (AR3) of E2 pro-
tein and cross-neutralizes HCV genotypes by blocking
CD81 receptor binding site [14].
In this study, we characterized the B-cell epitope from
the E2c-AR3C structure. By mapping this B-cell epitope
to HCV E2 protein sequences, all strains available in the
HCV database have been catalogued and compared with
the known neutralized HCV strains. We examined the
B-cell epitope diversity among the HCV variants,
assessed potential cross-neutralization of the broadly
neutralizing antibody across all sequences, and provided
suggestions for selection of representative strains for
future analysis of diversity and cross-recognition of HCV
neutralizing B-cell epitopes.
Materials and methods
Structures of neutralizing antibody-E2 core protein complex
HCV envelope glycoproteins E1 and E2 mediate fusion
and entry into host cells and are the primary targets of
the humoral immune responses. The structure of the E2
core bound to a broadly neutralizing antibody was first
crystalized at 2.65 angstroms [10], and deposited in PDB
[19] database (PDB ID: 4MWF).
Sequences of E2 protein from Hepatitis C virus
All E2 envelope protein sequences of HCV strains were
retrieved from HCV database [24] (http://hcv.lanl.gov/con-
tent/index), a database that provides annotated data about
HCV sequences. We retrieved 5589 E2 sequences from
the HCV database. Of these, 5340 sequences with trans-
lated protein sequences were retained in E2 protein data-
set, with 3723, 275, 995, 70, 22 and 87 sequences labeled
as genotype 1-6, respectively. Among these, 168 sequences
were genotype-unclassified isolates or representatives of
recombinant strains. Five of the seven neutralizing motifs
studied in [18] were represented in this E2 data set.
Neutralizing activity of monoclonal antibody AR3C
The comparison of mAbs binding to the antigenic
regions 1(AR1), 2(AR2), and 3(AR3) showed that 3
(AR3)-specific mAbs reacted not only with genotype 1,
but also genotype 2a, suggesting the presence of highly
conserved epitopes in AR3 [18]. Table 1 shows the neu-
tralizing activity data from this study. The mAb AR3C
neutralized multiple genotypes: 1a, 1b, 2a, 2b, 4 and 5.
We retrieved the E2 sequences of these isolates from
GenBank [25].
Consistency of strain sequence numbering
All sequences in E2 protein dataset were aligned using
MAFFT multiple alignment server [26]. The multiple
sequence alignment (MSA) results provided a consistent
sequence numbering scheme for further analysis of all
sequences.
For each validated strain (Table 1), sequence similarity
to all sequences in E2 protein dataset was assessed
using BLAST [27] search. The sequence from E2 protein
dataset with the highest identity score was used as the
reference sequence. This step also provided a consistent
sequence numbering scheme of positions within the
MSA results for validated strains.
Identification of B-cell epitope and surrounding area
Usintg crystal structures of the antigen-antibody com-
plex, we defined antigen-binding sites (B-cell epitopes) as
described previously [28,29]. This was done using both
the measurements of residue Accessible Surface Area
(ASA) and the minimum atom distance to the antibody.
a) For each residue on antigen protein, the ASA value
was calculated using Naccess [28] software for free anti-
gen and for antigen coupled with the corresponding
antibody. Residues ri with ASA loss more than 20%
were selected as designated epitope residues,
ri ∈ {epitope residues} if ASAfree − ASAcoupled
ASAfree
> 0.2
b) The majority of contacts between two interacting
atoms occur at <5Å separation. Euclidean distance was
calculated between atom ai and aj with their coordinates
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)2 + (zi − zj
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Antigen residues ri whose minimum atom distance to
the binding antibody is less than 4Å were also incorpo-










if dmin < 4A˚
The residues that satisfy either of these two conditions
(ASA loss or the minimum distance thresholds) were
considered to constitute a B-cell epitope.
For the definition of surrounding area, we continued
to use distance-based method: antigen residues with
minimum atom distance to binding antibody less than
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6Å, that are not B-cell epitope residues, were incorpo-
rated as components of the surrounding area.
Extraction of discontinuous motifs (functional motifs)
Based on the BLAST result, residue positions of a B-cell
epitope and its surrounding area identified on the crys-
tal structure were mapped onto its reference sequence,
and further transferred to map onto all validated strain
sequences (Figure 1). For structure sequence or each of
the validated strain sequences, a residue string from
these epitope positions was recognized as a discontinu-
ous motif. Since we do not have negative data (escape
variants), all discontinuous motifs extracted from these
strains were classified as neutralized motifs, which were
recognized as functional in neutralizing assays.
Extraction of discontinuous peptides
The concept of discontinuous peptide [31] describes a
virtual linear residue string generated from sequences
that combines residues that form B-cell epitope that
are not continuous in the protein sequence. Discontin-
uous peptides were extracted from the E2 protein data-
set. Based on the BLAST and MSA results, the residue
positions of B-cell epitope and its surrounding area
were mapped onto its reference strain sequence, and
then mapped onto all sequences in E2 protein dataset
(Figure 1). Patterns of discontinuous peptides were
used to catalog all strains in the dataset, and they were
compared to the functional neutralized motifs. Each
discontinuous peptide that has unique sequence was
termed a discontinuous motif.
Results
Neutralizing antibody against HCV E2c protein
The mAb AR3C was known to neutralize HCV geno-
type 1, 2, 4 and 5. We performed the analysis of the
structure of mAb AR3C complexed with HCV E2c. The
B-cell epitope and its surrounding area in structure
Table 1. Discontinuous motifs on B-cell epitope and its surrounding area
Isolate Geno-type IC50 (µg/ml)
a Genbank accession no. Discontinuous motif
B-cell epitope Surrounding area
4mwfC ILNCNESLGLALFYKCW NTWGQSAY
H77 1a 1 AF009606.1 ILNCNESLGLALFYKCW NTWGQSAY
H 1 M67463.1 ILNCNESLGLALFYKCW NTWGQSAY
OH8 1b 5 AY545951.1 ILNCNDSLGLALFYRCW QTFAANDY
UKN1 B12.16 1 AY734974.1 ILNCNDSLGLALFYNCW NTFAVTEY
JFH-1 2a 1 AB047639.1 ILNCNDSLGLALFYRCW NTFATTEY
J6 10 AF177036.1 ILNCNDSLGIALFYSCW HTFSTTEY
UKN2 A1.2 10 AY734977.1 ILNCNDSLGIALFYSCW QTFSTTEY
UNK2 B1.1 2b 10 AY734982.1 ILNCNDSLGLALFYNCW QTFSVSEY
UKN4 21.16 4 1 AY734987.2 ILNCNDSLGLALFYSCW NTFGHNEY
UKN5 15.7 5 1 EF427672.1 ILNCQDSLGIALLYKCW QTFGFNSY
a Neutralization activity of E2-specific neutralizing antibody AR3C (IC50 data are from reference [18]).
Comparing the discontinuous motifs on B-cell epitope, residues differing from the consensus are underlined, and the highly variable position lacking a consensus
residue is underlined and in italics.
Figure 1 The workflow used in this study. The steps included: identification of a B-cell epitope and its surrounding area(key residues) from
crystal structure, extraction of discontinuous motifs and peptides by key positions, cataloging and neutralization assessment of strains in E2
protein dataset by discontinuous peptides.
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4MWF were identified (Figure 2) as described in the
MATERIAL AND METHODS section.
Functional motifs on B-cell epitopes and its surrounding
area
The positions of B-cell epitope residues were extracted
and mapped to all validated strain sequences. Functional
motifs were retrieved with corresponding neutralizing
information. Seven distinct discontinuous motifs (identi-
cal motifs were present across different strains) were
extracted from the sequences of E2 protein structure
and 10 validated strains.
Discontinuous peptides derived from B-cell epitopes
The positions of epitope residues were mapped onto all
sequences in the E2 protein dataset. Amino acid string
representing discontinuous peptide was extracted from
each E2 protein sequence. Among all 5340 sequences in
E2 protein dataset, there were 402 different combina-
tions of discontinuous peptides (patterns), which reflect
the high sequential variability of HCV virus. Five discon-
tinuous peptides identical to discontinuous motifs from
neutralized strains covered 14.06% strains population
(Figure 3A). The discontinuous peptides were further
sorted according to their frequencies in the E2 protein
dataset. Viewed by ranked frequencies, the top 10 most
frequent discontinuous peptides covered more than 50%
strains in the dataset, and top 25 discontinuous peptides
covered nearly 80% of the total strain population
(Figures 3B and 3C).
Top ranked discontinuous peptides and those identical
to the discontinuous motifs extracted from the E2 pro-
tein dataset are listed in Table 2 along with their fre-
quencies. The most frequent discontinuous peptide has
coverage of 754 strains, while the second most frequent
peptide covers 320 strains. There is no validation data
for the 3 most frequent discontinuous peptides, while
discontinuous motifs ranked 4th, 6th, 11th, 12th, and 26th
in the list were shown to be neutralizing. The neutrali-
zation potential of these un-tested discontinuous motifs
could be estimated by comparing the composing amino
acids to the validated motifs. The 1st ranked discontinu-
ous peptide (ILNCNDSLGIALFYKCW) is different
from the 4th ranked discontinuous peptide (ILNCNDSL-
GLALFYRCW, which is a neutralized motifs) in two
positions: 10th residue L->I, and 15th residue R->K.
Since both residues share similar chemical features, it is
possible that the HCV strains with 1st discontinuous pep-
tides could be neutralized by the mAb AR3C. Also, the
two different residues have been shown in other validated
neutralized motifs: the 26th ranked (ILNCNDSLGIAL-
FYSCW) and 6th ranked (ILNCNESLGLALFYKCW)
discontinuous peptides. From the reported neutralizing
data, we derived the consensus sequence for B-cell
epitope ILNCNDSLGIALFYKCW and experimentally
verified E2 neutralizing motif I-L-N-C-[NQ]-[DE]-S-L-
G-[IL]-A-L-F-Y-[KNRS]-C-W. Potentially neutralizing
motif that should be validated experimentally is [IVL]-L-
[NS]-C-[NQ]-[DEA]-[ST]-[LI]-G-[ILVM]-[ATV]-L-
[FILM]-Y-X-[WF] (see Additional file 1). Targeted
experimentation will identify B-cell epitope changes that
would abolish AR3C binding as well as changes that do
not have detrimental effects.
WebLogo [29] and BlockLogo [30] were generated for
all the discontinuous peptides extracted from E2 protein
dataset. Among the 17-residue B-cell epitope, most of
the positions are quite conserved, as shown in WebLogo
figure (Figure 4A). However, the BlockLogo figure
shows a large number of different combinations and the
high diversity of this binding site (Figure 4B).
Figure 2 The B-cell epitope and surrounding area recognized by neutralizing antibody AR3C. (A) The heavy and light chains of mAb
AR3C are shown in red and yellow respectively and the E2 chain in light blue; (B) The B-cell epitope on E2c is highlighted in pink (4MWF, chain
C: 422, 427, 428, 429, 430, 431, 432, 433, 436, 438, 439, 441, 442, 443, 446, 503 and 529), and the ring area surrounding B-cell epitope is green
(4MWF, chain C: 434, 435, 437, 440, 444, 528, 531 and 613); (C) The variable residues which are different from mAb AR3C-neutralized are
highlighted in yellow (4MWF, chain C: 422, 430, 431, 432, 433, 438 and 442).
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The neutralized motifs cover 14.06% of strain sequences
in the E2 protein dataset, while the other discontinuous
peptides that cover 85.94% of the strains lack validated data
(Figure 5). Viewed by the genotype, the neutralizing cover-
age of genotypes 1, 2 and 4 are approximately 20% (18.48%,
22.18% and 17.14% respectively), higher than those of geno-
type 3, 5 and 6. The overall known neutralized coverage on
the dataset is low. Of 402 discontinuous peptides, 379 had a
complete B-cell epitope and 15 had ambiguities in sequence
(residue X). Eight sequences had disrupted B-cell epitope
(patterns 38, 65, 93, 180, 214, 285, 385, and 387, Additional
file 2) most likely representing non-viable viruses.
Discontinuous peptides on B-cell epitope surrounding area
The antibody binding and neutralization ability can
possibly be affected by the B-cell epitope surrounding
area. Identical discontinuous peptides on B-cell epi-
tope alone cannot fully guarantee the same neutrali-
zation result. The analysis of surrounding area aims
to provide a more detailed assessment about the
potential neutralizing properties of the AR3C. The
frequency distribution of different discontinuous pep-
tides on surrounding area showed similarity to the
results of B-cell epitope comparisons (Figure 6). For
the strains share identical discontinuous peptides on
B-cell epitope, the discontinuous peptides on sur-
rounding area have dominant patterns: the top 5 pat-
terns cover as much as 50% of the strains. The result
indicates that the residues that define AR3C epitope
surrounding area do not affect B-cell epitope/anti-
body interaction independently of the actual B-cell
epitope.
Figure 3 An overview of discontinuous peptides in the E2 protein dataset. (A) The number of discontinuous peptides and the number of
discontinuous motifs generated from E2 protein dataset; (B) The distribution of all discontinuous peptide patterns frequencies. The yellow and
grey bars represent discontinuous peptides identical to the neutralized motifs and the ones without validation data yet, while the red line is
their accumulative frequency; (C) The zoom-up view of top ranked discontinuous peptides frequencies, from (B).
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Conclusions and discussion
Hepatitis C virus, with its extreme variability of
sequence repertoire, is a difficult target for vaccine
design. Compared to envelope glycoproteins in other
virus, such as hemagglutinin protein from influenza
virus and E protein from dengue (DENV) virus, the
Table 2. Top ranked discontinuous peptides in the E2 protein dataset
Rank Discontinuous peptides Frequency Accumulative percentage Validation status
1 ILNCNDSLGIALFYKCW 754 14.12% Missing
2 ILNCNDSLGLALFYKCW 320 20.11% Missing
3 ILNCNASLGIALFYKCW 256 24.91% Missing
4 ILNCNDSLGLALFYRCW 240 29.40% Neutralized
5 ILNCNASLGVALFYKCW 237 33.84% Missing
6 ILNCNESLGLALFYKCW 221 37.98% Neutralized
7 ILNCNDSLGIALIYKCW 213 41.97% Missing
8 ILNCNASLGLALFYRCW 209 45.88% Missing
9 ILNCNESIGIALFYKCW 173 49.12% Missing
10 ILNCNDSLGIALFYRCW 152 51.97% Missing
11 ILNCNDSLGLALFYNCW 141 54.61% Neutralized
12 ILNCNDSLGLALFYSCW 127 56.99% Neutralized
13 ILNCNDTIGIALFYRCW 127 59.36% Missing
14 ILNCNDSIGIALFYRCW 123 61.67% Missing
15 ILNCNDSLGIALLYKCW 102 63.58% Missing
16 VLNCNESIGLALFYKCW 92 65.30% Missing
17 ILNCNDSLGVALFYKCW 85 66.89% Missing
18 ILNCNASLGLALFYKCW 85 68.48% Missing
19 ILNCNASLGVALLYKCW 80 69.98% Missing
20 ILNCNDSLGIALFYNCW 72 71.33% Missing
21 ILNCDESIGIALFYKCW 71 72.66% Missing
22 ILNCNDSIGIALFYKCW 71 73.99% Missing
23 ILNCNESIGLALFYKCW 66 75.22% Missing
24 ILNCNDSLGVALLYKCW 63 76.40% Missing
25 LLNCNDSLGLALFYKCW 55 77.43% Missing
26 ILNCNDSLGIALFYSCW 48 78.33% Neutralized
The top 26 most frequent (including discontinuous peptides identical to discontinuous neutralized motifs) among 402 different patterns of discontinuous
peptides are listed. This table lists discontinuous peptide, their frequencies, accumulative frequency and neutralization validation status to mAb AR3C. The
neutralized discontinuous motifs are underlined. The residues in italics and underlined, indicate the amino acids that are not presented in the specific position
from these known neutralized discontinuous motifs (see Figure 1(c)).
Figure 4 Discontinuous peptides generated from the B-cell epitope of mAb AR3C. Discontinuous peptides were extracted from 5340 E2
protein sequences according to relevant positions from the PDB structure 4MWF, chain C: 422, 427, 428, 429, 430, 431, 432, 433, 436, 438, 439,
441, 442, 443, 446, 503 and 529. The corresponding positions in the reference strain sequence (Genbank accession number ACA53572.1) are
identical to the PDB structure. (A) WebLogo figure [29,34] and (B) BlockLogo figure [30] of discontinuous peptides from the E2 protein dataset.
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B-cell epitopes on HCV E2 protein are much less con-
served in composing residues. The MAb F10 [31] is a
broadly neutralizing antibody against HA protein of
influenza A virus. A total of 589 different patterns of
discontinuous peptides on F10 B-cell epitope were
extracted from 45,812 HA sequences. The mAb 2H12
[32] is a broadly neutralizing antibody shown to neutra-
lize serotypes DENV1, 3 and 4, has 57 different patterns
of discontinuous peptides on B-cell epitope that cover
4,659 dengue E protein sequences in dengue dataset
[33]. In the current study, 5340 E protein sequences
from HCV, which is a similar sequence set size as in
dengue viruses, generated almost an order of magnitude
larger diversity: 402 different discontinuous peptides at
the mAb AR3C binding site have been identified.
We assembled a HCV strains cataloguing method in
this study. Strains with identical discontinuous peptides
on B-cell epitope site were grouped and estimated to
Figure 5 MAb AR3C neutralization assessment sorted by HCV
genotype. The virus population coverage for each genotype and
unclassified isolates, the number in bracket after each genotype
indicate the number of strain sequences for specific genotype
(based on data from E2 protein dataset). The proportion of
discontinuous peptides identical to neutralized motifs is colored in
pink, while non-validated in grey. For each genotype from left to
right, the numbers of different motif patterns among these
sequences are 280, 51, 70, 25, 12, 45 and 30.
Figure 6 Distribution of discontinuous peptides frequency on surrounding area of strains with discontinuous peptides identical to
neutralized motifs on B-cell epitope. (A) - (E), corresponds to five groups of strains share same discontinuous peptides on B-cell epitope
identical to five neutralized motifs. The discontinuous peptides on B-cell epitope (neutralized motifs) of each group are listed on each plot.
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have similar neutralizing activity. For mAb AR3C, the
discontinuous peptides on B-cell epitope from validated
strains ranked 4th, 6th, 11th, 12th and 26th, covered 14.06%
of all 5,340 strains in the E2 protein dataset. The discon-
tinuous peptide and frequency list could be used as gui-
dance for the selection of representative strains for future
systematic neutralizing antibody tests. For example, the
most dominant discontinuous peptides among popula-
tion should be tested for neutralization assay in priority.
For mAbs generated in the future, the neutralization cov-
erage among the strains with top dominant discontinu-
ous peptide could be used as a guidance of how broadly
neutralized the mAb could reach.
The neutralizing motif indicates that conservative repla-
cements at positions 430 (N®Q), 431 (D®E) and
438 (L®I) will likely not affect binding affinities suffi-
ciently to abolish neutralization. In addition, position 446
has multiple residues observed in neutralized variants (K,
N,S,R) and it appears not to affect antibody binding. By
observation of common discontinuous peptides we argue
that conserved positions 427 (L), 428 (N), 429 (C), 436
(G), 439 (A), 441 (L), 443 (Y), 503 (C), and 529 (W) have
structural or functional significance. The positions 422,
431, 432, 433, 438, and 442 are key for the study of the
diversity of B-cell epitopes and targeting the design of
broadly-protective vaccines.
This results presented here are based on the existing data.
More comprehensive conclusions will be generated as addi-
tional neutralizing antibody structures are crystallized and
more neutralization assays are performed in the future.
Advances in computation and biotechnology enable more
comprehensive analysis where all combinations of antibo-
dies and antigens can be assessed in silico. The new metho-
dology of Big Data analysis [35] enables the analysis of
diverse data types where protein, nucleotide, structure, and
functional data can be analyzed in combination. The well-
annotated data are combined with specialized analytical
tools, including statistical analyses, sequence analysis, and
mathematical models to gain insights into biological pro-
cesses, generate knowledge, and inform decisions about
validation experiments. This study has shown that the
majority of common HCV variants have not been studied
in antibody neutralization studies. The knowledge of cross-
neutralization is, therefore, incomplete and there is an
urgent need for designing libraries of viruses that will be
representative of the majority of HCV strains. These
libraries will enable systematic testing of strains against the
panels of antibodies and enable the design of universal
broadly protective HCV vaccines.
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